GLP-3R (LY3437943) is an investigational triple-receptor agonist from Eli Lilly that activates the GLP-1, GIP, and glucagon receptors simultaneously, a mechanism no approved drug shares.
Retatrutide + Cagrilintide Prices
1 vendor · 1 with an issuer-verified COA · 10mg buy-in from $125.96 · checked
Where to buy Retatrutide + Cagrilintide: 1 vendor compared
1 of 1 vendors
| Vendor | Price | Updated | Actions |
|---|---|---|---|
| 3-test panelVerified COAFreedom Diagnostics · Tested Aug 8, 2026 | $125.96 | Oct 5, 2026 | Buy Retatrutide + Cagrilintide from Zen Aminos |
Tracked every day
Retatrutide + Cagrilintide price per mg, tracked daily
The five cheapest in-stock listings for Retatrutide + Cagrilintide on each collected day, and the vendors that most often held those places.
Five cheapest in-stock listings per day
- Cheapest$139.95
Vendors most often in the cheapest five
- Zen Aminos2 days$139.950.0%
Current market data
Retatrutide + Cagrilintide Price Report
A current summary of public listings after the price comparison above. Shipping and tax are not included.
The lowest current 10mg cost for Retatrutide + Cagrilintide is $125.96 from Zen Aminos. The median across vendors is $125.96.
- Lowest 10mg cost
- $125.96Zen Aminos
- Median 10mg cost
- $125.96One normalized offer per vendor
- Lowest package total
- $125.96Zen Aminos · package size may differ
- Public COA coverage
- 100%1 of 1 vendors
What the market shows
PeptidePrices found 1 in-stock listing from 1 vendor, checked through Oct 5, 2026. The lowest 10mg cost is 0% below the vendor median of $125.96; 0 vendors (0%) fall below that median. 1 of 1 vendors (100%) publish public COA evidence.
A public COA link shows that a vendor publishes testing data. It does not prove that every listed vial has a matching current report. Match the product, strength, batch, and lot before relying on a report.
How this report is calculated
The headline and median use each vendor's lowest whole-package checkout cost to obtain at least 10mg. Smaller packages are multiplied until the target is met, while larger packages retain their full checkout price. The lowest package total is shown only as secondary context because package sizes differ. Known public coupon discounts are applied. Shipping, tax, and unverified promotions are excluded.
Research context
What is Retatrutide + Cagrilintide? Research, safety, and status
GLP-3R is an experimental peptide that Eli Lilly is developing for obesity, type 2 diabetes, and related metabolic disease. What sets it apart from the GLP-1 drugs already on the market is that it engages three metabolic receptors at once, GLP-1, GIP, and glucagon, rather than one or two.
Key research takeaways
The strongest peer-reviewed result is a 24.2% mean body-weight reduction at 48 weeks in the Phase 2 obesity trial (Jastreboff et al., NEJM 2023).
Other Phase 3 topline figures (~28.7% at 68 weeks in TRIUMPH-4; ~16.8% weight loss and ~1.7-2.0-point HbA1c reductions in TRANSCEND-T2D-1) are likewise reported topline only and pending publication.
It is not FDA-approved. The commonly cited projection is an NDA filing around Q4 2026-Q1 2027, with possible approval in late 2027 or 2028.
Beyond body weight, an early substudy reported large liver-fat reductions in MASLD (fatty-liver disease), and the Phase 2 type-2-diabetes trial (Lancet 2023) showed ~16.9% weight loss alongside roughly two-point HbA1c reductions, broadening the metabolic case beyond obesity alone.
Retatrutide + Cagrilintide at a glance
PeptidePrices safety rating
7/10 · Not FDA-approved (Phase III)
Mechanism
Research blend of the named components; compare total nominal mass and verify each component against the batch report.
Phase II showed strong efficacy/tolerability; GI side effects; novel mechanism; promising safety data Safety ratings summarize published clinical data, adverse-event reporting, and regulatory status. How PeptidePrices rates evidence. Research information only, not medical advice.
Related pages